Corrigendum to “The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017” [Eur J Canc 145 (2021) 11–18] - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2021

Corrigendum to “The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017” [Eur J Canc 145 (2021) 11–18]

Résumé

No abstract available

Domaines

Cancer

Dates et versions

hal-03629992 , version 1 (04-04-2022)

Identifiants

Citer

Marc Rodwin, Julien Mancini, Ségolène Duran, Anne-Céline Jalbert, Patrice Viens, et al.. Corrigendum to “The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017” [Eur J Canc 145 (2021) 11–18]. European Journal of Cancer, 2021, 152, pp.259-261. ⟨10.1016/j.ejca.2021.04.018⟩. ⟨hal-03629992⟩
17 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More